Understanding how RAS pathway inhibitors work in different cancer types
Mechanisms determining tumor-selective potency of RAS pathway inhibitors
This study is looking at how well certain drugs can help people with cancers that have changes in the RAS or BRAF genes, focusing on making sure the drugs work on cancer cells without harming healthy ones.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11003724 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of RAS pathway inhibitors in treating cancers with mutations in the RAS or BRAF genes. It aims to understand how these inhibitors can selectively target cancer cells while minimizing effects on normal cells. By studying the binding of these drugs to different proteins in cancer cells, the researchers hope to develop better treatment strategies for patients with RAS-mutant tumors. The study will involve laboratory experiments to analyze how RAS activation influences drug effectiveness and toxicity.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with RAS-mutant tumors who are seeking new treatment options.
Not a fit: Patients with RAS-WT (wild-type) tumors or those without any RAS or BRAF mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with RAS-mutant cancers.
How similar studies have performed: Previous research has shown promising results in targeting the RAS pathway in other cancer types, suggesting potential for success in this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Poulikakos, Poulikos I — Icahn School of Medicine at Mount Sinai
- Study coordinator: Poulikakos, Poulikos I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.